Literature DB >> 17250670

Three children with Milroy disease and de novo mutations in VEGFR3.

C Carver, G Brice, S Mansour, P Ostergaard, P Mortimer, S Jeffery.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17250670     DOI: 10.1111/j.1399-0004.2007.00741.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


× No keyword cloud information.
  7 in total

Review 1.  From germline towards somatic mutations in the pathophysiology of vascular anomalies.

Authors:  Nisha Limaye; Laurence M Boon; Miikka Vikkula
Journal:  Hum Mol Genet       Date:  2009-04-15       Impact factor: 6.150

Review 2.  Vascular anomalies: from genetics toward models for therapeutic trials.

Authors:  Melanie Uebelhoer; Laurence M Boon; Miikka Vikkula
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

Review 3.  Genetics of lymphatic anomalies.

Authors:  Pascal Brouillard; Laurence Boon; Miikka Vikkula
Journal:  J Clin Invest       Date:  2014-03-03       Impact factor: 14.808

4.  Analysis of the coding regions of VEGFR3 and VEGFC in Milroy disease and other primary lymphoedemas.

Authors:  F C Connell; P Ostergaard; C Carver; G Brice; N Williams; S Mansour; P S Mortimer; Steve Jeffery
Journal:  Hum Genet       Date:  2008-11-12       Impact factor: 4.132

5.  [Primary congenital lymphedema: Milroy disease: the first case observed in the Department of Pediatrics at the University Hospital Yalgado Ouedraogo, Ouagadougou].

Authors:  Chantal Zoungrana Ouattara; Angèle Kalmogho; Caroline Yonaba; Chantal Gabrielle Bouda; Ghislaine Yaméogo; Ludovic Kam
Journal:  Pan Afr Med J       Date:  2017-05-09

6.  FLT4 Mutations Are Associated with Segmental Lymphatic Dysfunction and Initial Lymphatic Aplasia in Patients with Milroy Disease.

Authors:  Ningfei Liu; Minzhe Gao
Journal:  Genes (Basel)       Date:  2021-10-13       Impact factor: 4.096

7.  Kampo Extract of Shinbuto Improved Refractory Diarrhea in Milroy's Disease.

Authors:  Yuko Horiba; Tetsuhiro Yoshino; Kenji Watanabe
Journal:  Glob Adv Health Med       Date:  2013-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.